Format

Send to

Choose Destination
Aliment Pharmacol Ther. 2001 Aug;15(8):1177-85.

There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia.

Author information

1
Department of Hépato-Gastroentérologie, CHU de Nantes, Nantes, France. bruley@easynet.fr

Abstract

BACKGROUND:

The relationship between Helicobacter pylori infection and non-ulcer dyspepsia is not established.

AIM:

To determine whether eradication of H. pylori might be of benefit in non-ulcer dyspepsia patients.

METHODS:

We randomly assigned 129 H. pylori infected patients with severe epigastric pain, without gastro-oesophageal reflux symptoms, to receive twice daily treatment with 300 mg of ranitidine, 1000 mg of amoxicillin, and 500 mg of clarithromycin for 7 days and 124 such patients to receive identical-appearing placebos.

RESULTS:

Treatment was successful (decrease of symptoms at 12 months) in 62% of patients in the active-treatment group and in 60% of the placebo group (N.S.). At 12 months, the rate of eradication of H. pylori was 69% in the active-treatment group and 18% in the placebo group (P < 0.001). Complete relief of symptoms occurred significantly more frequently in patients on the active treatment (43%) than in placebo-treated patients (31%, P=0.048). Within the active-treatment group, therapeutic success was significantly more frequent in the non-infected patients (84% vs. 64%, P=0.04).

CONCLUSIONS:

Although eradicating H. pylori is not likely to relieve symptoms in the majority of patients with non-ulcer dyspepsia, a small proportion of H. pylori-infected patients may benefit from eradication treatment.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center